source
- FDA finds Capricor's Duchenne stem cell therapy failed to meet Phase 3 goals, contradicting company claimsThe U.S. Food and Drug Administration announced that the stem cell treatment from Capricor Therapeutics did not achieve the primary objectives in its Phase 3 trial for Duchenne muscular dystrophy.…
- GSK announces $2.5 billion annual cost-cutting plan to offset upcoming patent cliffGSK disclosed in its latest quarterly earnings that it will launch a three-year restructuring aimed at saving about £1.9 billion ($2.5 billion) each year. The plan is intended to cushion the impac…